ArticlePediatrics2025
Trends in Lower Respiratory Tract Diagnoses and Nonrecommended Bronchiolitis Therapies.
Article in Pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveDifferentiating bronchiolitis from other lower respiratory tract (LRT) diagnoses is challenging because of shared clinical features. We hypothesized that recently reported decreases in nonrecommended bronchiolitis therapies may be overestimated because of shifts in diagnostic assignment.
methodsWe performed a multicenter retrospective cohort study across 40 hospitals from 2010 to 2022 using the Pediatric Health Information Systems database. For children aged younger than 2 years with LRT discharge diagnoses, we analyzed trends in (1) the proportion of encounters with assigned diagnosis of bronchiolitis, asthma (including "reactive airway disease"), and pneumonia and (2) the receipt of bronchodilators, systemic steroids, and/or antibiotics.
resultsWe identified 1 023 745 encounters with an LRT diagnosis. The proportion of LRT conditions diagnosed as bronchiolitis increased from 55.4% to 79.6% (adjusted incidence rate ratio [aIRR], 1.022; 95% CI, 1.019-1.026), signifying a relative increase of 2.2% per year, while asthma decreased from 22.1% to 6.1% (aIRR, 0.918; 95% CI, 0.897-0.939), and pneumonia decreased from 12.5% to 4.7% (aIRR, 0.925; 95% CI, 0.913-0.937). Across all LRT diagnoses, bronchodilator and steroid use decreased from 49.5% to 28.6% (aIRR, 0.947; 95% CI, 0.936-0.958) and 23.3% to 18.4% (aIRR, 0.982; 95% CI, 0.972-0.992), respectively. Similarly, antibiotic use declined from 13.9% to 10% (aIRR, 0.975; 95% CI, 0.962-0.989). Revisits with LRT diagnoses were unchanged.
conclusionsThe proportion of LRT conditions identified as bronchiolitis has increased over time, while nonrecommended bronchiolitis therapies have decreased. Further exploration is needed to elucidate this relationship, which suggests a potential influence of therapeutic stewardship on ultimate diagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.